| Primary |
| Product Used For Unknown Indication |
11.2% |
| Fungal Infection |
10.6% |
| Aspergillosis |
9.4% |
| Acute Lymphocytic Leukaemia |
8.2% |
| Bronchopulmonary Aspergillosis |
7.6% |
| Drug Use For Unknown Indication |
7.6% |
| Candidiasis |
7.1% |
| Sepsis |
5.3% |
| Zygomycosis |
4.7% |
| Meningitis Cryptococcal |
4.1% |
| Evidence Based Treatment |
3.5% |
| Meningitis |
3.5% |
| Mucormycosis |
3.5% |
| Febrile Neutropenia |
2.9% |
| Coccidioidomycosis |
2.4% |
| Acute Myeloid Leukaemia |
1.8% |
| Antifungal Prophylaxis |
1.8% |
| Immunosuppression |
1.8% |
| Prophylaxis |
1.8% |
| Bone Marrow Failure |
1.2% |
|
| Tachycardia |
13.5% |
| Hypertension |
11.2% |
| Tremor |
10.1% |
| Pyrexia |
9.0% |
| Respiratory Rate Increased |
9.0% |
| Chills |
5.6% |
| Tachypnoea |
5.6% |
| Oxygen Saturation Decreased |
4.5% |
| Heart Rate Increased |
3.4% |
| Renal Impairment |
3.4% |
| Thrombocytopenia |
3.4% |
| Wheezing |
3.4% |
| Blood Creatinine Increased |
2.2% |
| Blood Glucose Increased |
2.2% |
| Blood Pressure Increased |
2.2% |
| Condition Aggravated |
2.2% |
| Death |
2.2% |
| Drug Ineffective |
2.2% |
| Fungal Infection |
2.2% |
| Hypertensive Crisis |
2.2% |
|
| Secondary |
| Drug Use For Unknown Indication |
17.9% |
| Product Used For Unknown Indication |
17.3% |
| Acute Myeloid Leukaemia |
13.5% |
| Bronchopulmonary Aspergillosis |
9.0% |
| Aspergillosis |
7.7% |
| Hiv Infection |
5.1% |
| Meningitis Cryptococcal |
4.5% |
| Mycobacterium Avium Complex Infection |
3.8% |
| Convulsion Prophylaxis |
2.6% |
| Mucormycosis |
2.6% |
| Pneumonia |
2.6% |
| Anaplastic Astrocytoma |
1.9% |
| Cytomegalovirus Infection |
1.9% |
| Sepsis |
1.9% |
| Bacteraemia |
1.3% |
| Candida Sepsis |
1.3% |
| Infection Prophylaxis |
1.3% |
| Meningitis |
1.3% |
| Nephrogenic Diabetes Insipidus |
1.3% |
| Sinusitis |
1.3% |
|
| Hyperamylasaemia |
12.9% |
| Renal Failure |
6.5% |
| Rhabdomyolysis |
6.5% |
| Sciatica |
6.5% |
| Tachycardia |
6.5% |
| Therapeutic Product Contamination |
6.5% |
| Ventricular Extrasystoles |
6.5% |
| Weight Increased |
6.5% |
| White Blood Cell Count Decreased |
6.5% |
| Caecitis |
3.2% |
| Creatinine Renal Clearance Decreased |
3.2% |
| Hepatic Enzyme Increased |
3.2% |
| Nephrogenic Diabetes Insipidus |
3.2% |
| Obstructive Airways Disorder |
3.2% |
| Oedema Peripheral |
3.2% |
| Purulent Discharge |
3.2% |
| Renal Impairment |
3.2% |
| Respiratory Failure |
3.2% |
| Sepsis Syndrome |
3.2% |
| Staphylococcal Bacteraemia |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.9% |
| Drug Use For Unknown Indication |
15.4% |
| Acute Myeloid Leukaemia |
7.7% |
| Hiv Infection |
7.3% |
| Antifungal Prophylaxis |
5.4% |
| Pain |
4.8% |
| Pyrexia |
4.4% |
| Nausea |
4.1% |
| Oesophageal Candidiasis |
3.6% |
| Mycobacteria Test |
2.5% |
| Diarrhoea |
2.0% |
| Prophylaxis |
1.8% |
| Abdominal Discomfort |
1.4% |
| Abscess |
1.4% |
| Vaginal Haemorrhage |
1.4% |
| Abdominal Pain |
1.3% |
| Anaemia |
1.3% |
| Antiviral Prophylaxis |
1.1% |
| Constipation |
1.1% |
| Herpes Simplex |
1.1% |
|
| Thrombocytopenia |
29.0% |
| Deep Vein Thrombosis |
6.5% |
| Peripheral Motor Neuropathy |
6.5% |
| Shock |
6.5% |
| Anaemia |
4.8% |
| Pulmonary Embolism |
4.8% |
| Respiratory Failure |
4.8% |
| Sepsis |
4.8% |
| Acute Myeloid Leukaemia |
3.2% |
| Death |
3.2% |
| Swelling Face |
3.2% |
| Tachycardia |
3.2% |
| Urinary Hesitation |
3.2% |
| Vision Blurred |
3.2% |
| Weight Increased |
3.2% |
| Wheezing |
3.2% |
| Cardiac Failure |
1.6% |
| Drug Resistance |
1.6% |
| Dyspnoea |
1.6% |
| Emotional Disorder |
1.6% |
|
